SCHEMBL42898

SCHEMBL42898

CCCCCN(CCCCC)c1ccc(C=Cc2cc[n+](C)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.56
CHRM4 P08173 2/20 0.56
CHRM5 P08912 2/20 0.56
CHRM1 P11229 2/20 0.56
CHRM3 P20309 2/20 0.56
ALDH1A1 P00352 3/20 0.54
MAPT P10636 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MEN1 O00255 1/20 0.54
LMNA P02545 1/20 0.54
ALPG P10696 1/20 0.54
THRB P10828 1/20 0.54
HTT P42858 1/20 0.54
GFER P55789 1/20 0.54
KMT2A Q03164 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
KDM4A O75164 4/20 0.52
KDM2A Q9Y2K7 4/20 0.52
INSR P06213 2/20 0.47
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5128472 1.00 CHRM2 (0.56) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL3054036 0.98 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL7619893 0.98 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL3054039 0.98 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL16183107 0.98 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL10340880 0.98 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL10341023 0.98 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL10340879 0.98 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL10341093 0.98 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL10340951 0.98 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3131655-B1 METHOD FOR THE QUANTIFICATION OF PARASITE EGGS IN FECES MEP Equine Solutions LLC (US) 2020-12-02 EP claimed
US-10094829-B2 Method for the quantification of parasite eggs in feces MEP Equine Solutions LLC (US) 2018-10-09 US claimed
US-9933425-B2 Method for the quantification of parasite eggs in feces MEP Equine Solutions LLC (US) 2018-04-03 US claimed
US-20180074055-A1 METHOD FOR THE QUANTIFICATION OF PARASITE EGGS IN FECES Parasight System Inc. 2018-03-15 US claimed
US-20150293091-A1 METHOD FOR THE QUANTIFICATION OF PARASITE EGGS IN FECES Parasight System Inc. 2015-10-15 US claimed
US-8383415-B2 Hydrogel composition to enhance fluorescence DSO NATIONAL LABORATORIES (SG) 2013-02-26 US claimed
EP-4707406-A2 DETERMINATION OF POLYMORPHISMS USING ISOTHERMAL NUCLEIC ACID AMPLIFICATION Abbott Diagnostics Scarborough, Inc. (US) 2026-03-11 EP disclosed
US-12566186-B2 Assays for detecting the presence or amount of an anti-drug antibody GENZYME CORPORATION (US) 2026-03-03 US disclosed
US-20260015656-A1 DETERMINATION OF POLYMORPHISMS USING ISOTHERMAL NUCLEIC ACID AMPLIFICATION ABBOTT DIAGNOSTICS SCARBOROUGH INC (US) 2026-01-15 US disclosed
US-20250263786-A1 DETERMINATION OF POLYMORPHISMS USING ISOTHERMAL NUCLEIC ACID AMPLIFICATION ABBOTT DIAGNOSTICS SCARBOROUGH, INC. 2025-08-21 US disclosed
EP-4582812-A2 ASSAYS FOR DETECTING THE PRESENCE OR AMOUNT OF AN ANTI-DRUG ANTIBODY Genzyme Corporation (US) 2025-07-09 EP disclosed
EP-4137816-B1 ASSAYS FOR DETECTING THE PRESENCE OR AMOUNT OF AN ANTI-DRUG ANTIBODY GENZYME CORP (US) 2025-03-19 EP disclosed
CN-119120674-A Method and kit for detecting activity of recombinase 深圳市真迈生物科技有限公司 2024-12-13 CN disclosed
US-20090004461-A1 Metal-Enhanced Fluorescence from Plastic Substrates UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE (US) 2009-01-01 US disclosed
US-20080317768-A1 BIOCONJUGATED NANOPARTICLES BOEING COMPANY (US) 2008-12-25 US disclosed
US-20080286880-A1 Methods and Systems for Nanoparticle Enhancement of Signals THE PENN STATE RESEARCH FOUNDATION (US) 2008-11-20 US disclosed
US-20070269826-A1 ANGULAR-DEPENDENT METAL-ENHANCED FLUORESCENCE UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE (US) 2007-11-22 US disclosed
WO-2007043973-A1 METHOD OF ENHANCING A FLUORESCENT SIGNAL DSO NATIONAL LABORATORIES (SG) 2007-04-19 WO disclosed
US-20050202464-A1 Radiative decay engineering UNIVERSITY OF MARYLAND, BALTIMORE 2005-09-15 US disclosed
US-20030228682-A1 Fluorescence sensing UNIVERSITY OF MARYLAND, BALTIMORE 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015656-A1 DETERMINATION OF POLYMORPHISMS USING ISOTHERMAL NUCLEIC ACID AMPLIFICATION RPA1, RAD54L, RPAP1 CHRM2 4829/4885CHRM4 4389/4885CHRM5 4698/4885
US-12566186-B2 Assays for detecting the presence or amount of an anti-drug antibody ADA, ADAR, HLA-A CHRM2 2297/4885CHRM4 2256/4885CHRM5 3223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.